Company Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies.
It operates through two segments: Plinabulin pipeline and TPD platform. The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.
It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer.
Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration.
The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
| Country | United States |
| Founded | 2010 |
| IPO Date | Mar 9, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Lan Huang |
Contact Details
Address: 100 Campus Drive, 4th Floor, Suite 410 Florham Park, New Jersey 07932 United States | |
| Phone | 646-305-6387 |
| Website | beyondspringpharma.com |
Stock Details
| Ticker Symbol | BYSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001677940 |
| CUSIP Number | G10830100 |
| ISIN Number | KYG108301006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lan Huang Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. June Lu Ph.D. | Chief Scientific Officer |
| Stephen Kilmer | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | EFFECT | Notice of Effectiveness |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 13, 2025 | POS AM | Post-Effective amendments for registration statement |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | 8-K | Current Report |
| Aug 6, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 3, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |